Abstract:Background: The COVID-19 agent, SARS-CoV-2, is conspecific with SARS-CoV, the causal agent of the severe acute respiratory syndrome epidemic in 2002-03. Although the viruses share a completely homologous repertoire of proteins and use the same cellular entry receptor, their transmission efficiencies and pathogenetic traits differ. We aimed to compare interferon antagonism by SARS-CoV and SARS-CoV-2. Methods: For this functional study, we infected Vero E6 and Calu-3 cells with strains of SARS-CoV and SARS-CoV-2. We studied differences in cell line-specific replication (Vero E6 vs Calu-3 cells) and analysed these differences in relation to TMPRSS2-dependent cell entry based on inhibition with the drug camostat mesilate. We evaluated viral sensitivity towards type I interferon treatment and assessed cytokine induction and type I interferon signalling in the host cells by RT-PCR and analysis of transcription factor activation and nuclear translocation. Based on reverse genetic engineering of SARS-CoV, we investigated the contribution of open reading frame 6 (ORF6) to the observed phenotypic differences in interferon signalling, because ORF6 encodes an interferon signalling antagonist. We did a luciferase-based interferon-stimulated response element promotor activation assay to evaluate the antagonistic capacity of SARS-CoV-2 wild-type ORF6 constructs and three mutants (Gln51Glu, Gln56Glu, or both) that represent amino acid substitutions between SARS-CoV and SARS-CoV-2 protein 6 in the carboxy-terminal domain. Findings: Overall, replication was higher for SARS-CoV in Vero E6 cells and for SARS-CoV-2 in Calu-3 cells. SARS-CoV-2 was reliant on TMPRSS2, found only in Calu-3 cells, for more efficient entry. SARS-CoV-2 was more sensitive to interferon treatment, less efficient in suppressing cytokine induction via IRF3 nuclear translocation, and permissive of a higher level of induction of interferon-stimulated genes MX1 and ISG56. SARS-CoV-2 ORF6 expressed in the context of a fully replicating SARS-CoV backbone suppressed MX1 gene induction, but this suppression was less efficient than that by SARS-CoV ORF6. Mutagenesis showed that charged amino acids in residues 51 and 56 shift the phenotype towards more efficient interferon antagonism, as seen in SARS-CoV. Interpretation: SARS-CoV-2 ORF6 interferes less efficiently with human interferon induction and interferon signalling than SARS-CoV ORF6. Because of the homology of the genes, onward selection for fitness could involve functional optimisation of interferon antagonism. Charged amino acids at positions 51 and 56 in ORF6 should be monitored for potential adaptive changes. Funding: Bundesministerium für Bildung und Forschung, EU RECOVER project.

Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Differential Interferon-Α Subtype Induced Immune Signatures Are Associated with Suppression of SARS-CoV-2 Infection.

Activation and evasion of type I interferon responses by SARS-CoV-2

Type I interferons and SARS-CoV-2: from cells to organisms

Differential interferon-α subtype immune signatures suppress SARS-CoV-2 infection

Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway.

Interferon-stimulated genes and their antiviral activity against SARS-CoV-2

Evasion of Type I Interferon by SARS-CoV-2

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome

Comparative Transcriptome Analysis of SARS-CoV-2, SARS-CoV, MERS-CoV, and HCoV-229E Identifying Potential IFN/ISGs Targets for Inhibiting Virus Replication

SARS-CoV-2 Infection Activates a Subset of Intrinsic Pathways to Inhibit Type I Interferons in Vitro and in Vivo

A Commentary of “type I Interferon Deficiency Can Lead to Severe COVID-19” in 10 Remarkable Discoveries from 2020 in Nature

Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) and Spike (S) Proteins Antagonize Host Type I Interferon Response

Serum Levels of Type I Interferon (IFN-I) is Associated with the Severity of COVID-19.

Competitive Endogenous RNA Network Activates Host Immune Response in SARS-CoV-2-, panH1N1 (A/California/07/2009)-, and H7N9 (A/Shanghai/1/2013)-Infected Cells

Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics

SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon